# Acorda Therapeutics clinical trials: 38 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 38 trials with Acorda Therapeutics as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Acorda Therapeutics: 38 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/acorda-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 38
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 38, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 25, 2019 | NCT03887884 | Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) | Acorda Therapeutics | Phase 1 | Completed | Parkinson's Disease | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03887884) |
| September 19, 2016 | NCT02905227 | A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder | Acorda Therapeutics | Phase 1 | Completed | Migraine | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02905227) |
| June 24, 2016 | NCT02812394 | A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets | Acorda Therapeutics | Phase 1 | Completed | Parkinson Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02812394) |
| June 21, 2016 | NCT02807675 | A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder) | Acorda Therapeutics | Phase 1 | Completed | Parkinson's Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02807675) |
| January 26, 2016 | NCT02663999 | A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers | Acorda Therapeutics | Phase 1 | Completed | Healthy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02663999) |
| December 17, 2015 | NCT02633839 | A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking... | Acorda Therapeutics | Phase 1 | Completed | Smoking | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02633839) |
| December 17, 2015 | NCT02633007 | A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With... | Acorda Therapeutics | Phase 1 | Completed | Asthma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02633007) |
| November 20, 2015 | NCT02609945 | Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults | Acorda Therapeutics | Phase 1 | Completed | Migraine | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02609945) |
| June 17, 2015 | NCT02474407 | Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) | Acorda Therapeutics | Phase 2 | Terminated | Refractory Epilepsy | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02474407) |
| April 22, 2015 | NCT02422940 | Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. | Acorda Therapeutics | Phase 3 | Terminated | Post-ischemic Stroke | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02422940) |
| March 25, 2015 | NCT02398461 | An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse | Acorda Therapeutics | Phase 1 | Completed | Multiple Sclerosis, Acute Relapsing | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02398461) |
| February 2, 2015 | NCT02352363 | Randomized Safety Study of CVT-301 Compared to an Observational Control Group | Acorda Therapeutics | Phase 3 | Completed | Idiopathic Parkinson's Disease | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02352363) |
| December 15, 2014 | NCT02316847 | An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray. | Acorda Therapeutics | Phase 2 | Terminated | Epilepsy | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02316847) |
| October 22, 2014 | NCT02271217 | A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. | Acorda Therapeutics | Phase 3 | Completed | Post-Ischemic Stroke | 377 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02271217) |
| September 17, 2014 | NCT02242487 | Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes | Acorda Therapeutics | Phase 3 | Completed | Idiopathic Parkinson's Disease | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02242487) |
| September 15, 2014 | NCT02240030 | Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes | Acorda Therapeutics | Phase 3 | Completed | Idiopathic Parkinson's Disease | 351 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02240030) |
| September 18, 2013 | NCT01944683 | A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam... | Acorda Therapeutics | Phase 1 | Completed | Heart Failure | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01944683) |
| April 24, 2013 | NCT01839279 | A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using... | Acorda Therapeutics | Phase 2 | Completed | Spasticity | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01839279) |
| March 4, 2013 | NCT01803867 | An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis | Acorda Therapeutics | Phase 1 | Completed | Multiple Sclerosis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01803867) |
| January 29, 2013 | NCT01777555 | Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes | Acorda Therapeutics | Phase 2 | Completed | Idiopathic Parkinson's Disease | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01777555) |
| December 17, 2012 | NCT01750684 | AC105 in Patients With Acute Traumatic Spinal Cord Injury | Acorda Therapeutics | Phase 2 | Terminated | Acute Spinal Cord Injury | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01750684) |
| September 12, 2012 | NCT01683838 | Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury | Acorda Therapeutics | Phase 3 | Completed | Spinal Cord Injury, Muscle Spasticity | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01683838) |
| June 12, 2012 | NCT01617135 | Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes | Acorda Therapeutics | Phase 2 | Completed | Idiopathic Parkinson's Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01617135) |
| May 25, 2012 | NCT01605825 | A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke | Acorda Therapeutics | Phase 2 | Completed | Ischemic Stroke | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01605825) |
| February 20, 2012 | NCT01535664 | An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With... | Acorda Therapeutics | Observational | Completed | Multiple Sclerosis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01535664) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 2 | 9 |
| Phase 3 | 13 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |
| Terminated | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Sclerosis | 9 |
| Parkinson Disease | 8 |
| Muscle Spasticity | 4 |
| Demyelinating Diseases | 4 |
| Spinal Cord Injuries | 3 |
| Epilepsy | 3 |
| Migraine Disorders | 2 |
| Asthma | 2 |
| Ischemic Stroke | 2 |
| Seizures | 2 |
| Heart Failure | 2 |
| Cerebral Palsy | 1 |
| Drug Resistant Epilepsy | 1 |
| Multiple Sclerosis, Relapsing-Remitting | 1 |
| Smoking | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [B2B domestic trade companies in the United States](https://specstream.ai/data/businesses/b2b-domestic-trade-companies/united-states)
- [Grout companies in the United States](https://specstream.ai/data/businesses/grout-companies/united-states)
- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
- [Business banking companies in the United States](https://specstream.ai/data/businesses/business-banking-companies/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
